Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PANK3 | Q9H999 | 11/20 | 0.56 |
| ▸ | BPTF | Q12830 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489225 | 0.85 | LMNA (0.57) | LMNAHTTCYP1A2PANK3BPTF | |
| SCHEMBL2068254 | 0.85 | PANK3 (0.59) | LMNAHTTCYP1A2PANK3BPTF | |
| SCHEMBL3827722 | 0.80 | KDM4E (0.43) | LMNAHTTPANK3BPTFTRPV1 | |
| SCHEMBL1393962 | 0.80 | KDM4E (0.43) | LMNAHTTPANK3BPTFMEN1 | |
| SCHEMBL15475993 | 0.80 | LMNA (0.55) | LMNAHTTCYP1A2PANK3BPTF | |
| SCHEMBL22489679 | 0.80 | LMNA (0.51) | LMNAHTTCYP1A2PANK3BPTF | |
| SCHEMBL9310615 | 0.79 | NPSR1 (0.57) | LMNAHTTPANK3TRPV1MEN1 | |
| SCHEMBL30778281 | 0.78 | TRPV1 (0.57) | LMNAHTTCYP1A2PANK3TRPV1 | |
| SCHEMBL1433407 | 0.78 | TRPV1 (0.57) | LMNAHTTCYP1A2PANK3TRPV1 | |
| SCHEMBL1977246 | 0.78 | LMNA (1.00) | LMNAHTTCYP1A2PANK3BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3474667-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | St. Jude Children's Research Hospital, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223474-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3027600-A1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | Novartis AG (CH) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017589-A1 | 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014109858-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2231656-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1701946-A2 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2006-09-20 | — | — | EP | disclosed |
| EP-1513835-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-08-16 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070910-A2 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-AVENTIS (FR) | 2005-08-04 | — | — | WO | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1419150-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003008407-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | LMNA 1792/4885HTT 769/4885CYP1A2 3700/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | LMNA 3481/4885HTT 4309/4885CYP1A2 246/4885 |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | LMNA 1792/4885HTT 769/4885CYP1A2 3700/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | LMNA 2720/4885HTT 3063/4885CYP1A2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.